Literature DB >> 3703609

Age-related alterations of immunoreactive pancreatic cationic trypsinogen in sera from cystic fibrosis patients with and without pancreatic insufficiency.

P R Durie, G G Forstner, K J Gaskin, D J Moore, G J Cleghorn, S S Wong, M L Corey.   

Abstract

Serum immunoreactive cationic trypsinogen levels were determined in 99 control subjects and 381 cystic fibrosis (CF) patients. To evaluate the status of the exocrine pancreas all CF patients had previously undergone fecal fat balance studies and/or pancreatic stimulation tests. Three hundred fourteen CF patients had fat malabsorption and/or had inadequate pancreatic enzyme secretion (pancreatic insufficiency) requiring oral pancreatic enzyme supplements with meals. Sixty-seven CF patients did not have fat malabsorption and/or had adequate enzyme secretion (pancreatic sufficiency) and were not receiving pancreatic enzyme supplements with meals. Mean serum trypsinogen in 99 control subjects was 31.4 +/- 14.8 micrograms/liter (+/- 2 SD) and levels did not vary with age or sex. In CF infants (less than 2 yr) with pancreatic insufficiency, mean serum trypsinogen was significantly above the non-CF values (p less than 0.001). Ninety-one percent of the CF infants had elevated levels. Serum trypsinogen values in the pancreatic insufficient group declined steeply up to 5 years, reaching subnormal values by age 6. An equation was developed which described these age-related changes very accurately. Only six CF patients with pancreatic insufficiency had serum trypsinogen levels above the 95% confidence limits of this equation. In contrast, there was no age related decline in serum trypsinogen among the CF group with pancreatic sufficiency. Under 7 yr, serum trypsinogen failed to distinguish the two groups. In those over 7 yr of age, however, serum trypsinogen was significantly higher than the CF group with pancreatic insufficiency (p less than 0.001), and 93% had values within or above the control range.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3703609     DOI: 10.1203/00006450-198603000-00002

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  18 in total

Review 1.  Bronchopulmonary dysplasia: early diagnosis, prophylaxis, and treatment.

Authors:  A Greenough
Journal:  Arch Dis Child       Date:  1990-10       Impact factor: 3.791

Review 2.  A rational approach to the nutritional care of patients with cystic fibrosis.

Authors:  P R Durie; P B Pencharz
Journal:  J R Soc Med       Date:  1989       Impact factor: 5.344

Review 3.  Uses and abuses of enzyme therapy in cystic fibrosis.

Authors:  P Durie; D Kalnins; L Ellis
Journal:  J R Soc Med       Date:  1998       Impact factor: 5.344

4.  Immunoreactive trypsin in Shwachman's syndrome.

Authors:  J F Dossetor; H C Spratt; C J Rolles; C P Seem; A F Heeley
Journal:  Arch Dis Child       Date:  1989-03       Impact factor: 3.791

5.  Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities.

Authors:  Weili Li; David Soave; Melissa R Miller; Katherine Keenan; Fan Lin; Jiafen Gong; Theodore Chiang; Anne L Stephenson; Peter Durie; Johanna Rommens; Lei Sun; Lisa J Strug
Journal:  Hum Genet       Date:  2013-09-22       Impact factor: 4.132

Review 6.  Modifier genes in Mendelian disorders: the example of cystic fibrosis.

Authors:  Garry R Cutting
Journal:  Ann N Y Acad Sci       Date:  2010-12       Impact factor: 5.691

7.  Serum immunoreactive cationic trypsinogen: a useful indicator of severe exocrine dysfunction in the paediatric patient without cystic fibrosis.

Authors:  D J Moore; G G Forstner; C Largman; G J Cleghorn; S S Wong; P R Durie
Journal:  Gut       Date:  1986-11       Impact factor: 23.059

8.  Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas.

Authors:  N Ahmed; M Corey; G Forstner; J Zielenski; L-C Tsui; L Ellis; E Tullis; P Durie
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

9.  Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease.

Authors:  T Shoshani; A Augarten; E Gazit; N Bashan; Y Yahav; Y Rivlin; A Tal; H Seret; L Yaar; E Kerem
Journal:  Am J Hum Genet       Date:  1992-01       Impact factor: 11.025

10.  Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report.

Authors:  Philip M Farrell; Beryl J Rosenstein; Terry B White; Frank J Accurso; Carlo Castellani; Garry R Cutting; Peter R Durie; Vicky A Legrys; John Massie; Richard B Parad; Michael J Rock; Preston W Campbell
Journal:  J Pediatr       Date:  2008-08       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.